We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ACRV

Price
1.62
Stock movement up
+0.09 (5.88%)
Company name
Acrivon Therapeutics, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
50.44M
Ent value
24.82M
Price/Sales
26.77
Price/Book
0.26
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-84.41%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-04-11

iO Charts is a Seeking Alpha partner

DIVIDENDS

ACRV does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales26.77
Price to Book0.26
EV to Sales13.17

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count31.14M
EPS (TTM)-2.02
FCF per share (TTM)-1.67

Income statement

Loading...
Income statement data
Revenue (TTM)1.88M
Gross profit (TTM)1.31M
Operating income (TTM)-85.30M
Net income (TTM)-76.98M
EPS (TTM)-2.02
EPS (1y forward)-2.96

Margins

Loading...
Margins data
Gross margin (TTM)69.59%
Operating margin (TTM)-4527.49%
Profit margin (TTM)-4085.83%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash43.41M
Net receivables0.00
Total current assets188.98M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment10.13M
Total assets214.68M
Accounts payable1.51M
Short/Current long term debt4.01M
Total current liabilities14.82M
Total liabilities17.79M
Shareholder's equity196.89M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-60.67M
Capital expenditures (TTM)3.09M
Free cash flow (TTM)-63.77M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-39.10%
Return on Assets-35.86%
Return on Invested Capital-38.89%
Cash Return on Invested Capital-32.22%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.55
Daily high1.62
Daily low1.45
Daily Volume109K
All-time high23.20
1y analyst estimate21.56
Beta-
EPS (TTM)-2.02
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
ACRVS&P500
Current price drop from All-time high-93.02%-12.89%
Highest price drop-94.14%-56.47%
Date of highest drop8 Apr 20259 Mar 2009
Avg drop from high-59.81%-11.07%
Avg time to new high75 days12 days
Max time to new high542 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ACRV (Acrivon Therapeutics, Inc. Common Stock) company logo
Marketcap
50.44M
Marketcap category
Small-cap
Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Employees
58
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...